Damage-targeted treatments of disease
OwnerErlinda M. Gordon, Frederick L. Hallinventors
Life of this patent
Estimating the term…
Abstract
Methods of treating viral infectious diseases such as coronavirus disease 2019 and other diseases causing organ damage in a subject are provided. Treatments include administration of a targeted retrovector to the subject. Among the effects of these treatments is the lessening or prevention of complications of the disease, particularly those arising from pathogenic immune responses.
Claims1
A method of lessening a complication from coronavirus disease 2019 (COVID-19) infection in a subject, wherein the complication is selected from the group consisting of cytokine release syndrome (CRS), acute respiratory distress syndrome (ARDS), kidney damage, and liver damage, comprising administering to the subject a dose of a murine leukemia virus (MLV)-based retroviral vector comprising a collagen-binding motif and encoding an N-terminal deletion mutant human cyclin G1 (CCNG1) construct, effective to reduce severity of the complication.
Dependencies are inferred from the claim text.